Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauricio Montano

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Biorxiv : the Preprint Server for Biology|August 16, 2024
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Immunity|March 21, 2026
Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV reboundTongcui Ma, Ashley F George, Zichong Li, et al.
Journal of Virology|February 4, 2021
Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity <i>Ex Vivo and In Vivo</i>Andrea Gramatica, Roland Schwarzer, William Brantley, et al.
Journal of Medicinal Chemistry|January 6, 2026
Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection ModelsLuca Lizzadro, Jiapeng Li, Taha Y Taha, et al.
Elife|November 19, 2025
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Medrxiv : the Preprint Server for Health Sciences|January 25, 2022
Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without VaccinationRahul K Suryawanshi, Irene P Chen, Tongcui Ma, et al.
JCI Insight|May 17, 2022
Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccinationYusuke Matsui, Lin Li, Mary Prahl, et al.
Science Advances|April 23, 2025
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M<sup>Pro</sup> inhibitors with potent in vivo efficacyTyler C Detomasi, Gilles Degotte, Sijie Huang, et al.
Cell|April 21, 2026
Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cellsUjjwal Rathore, Eli Dugan, Hunter Thornton, et al.
Nature|May 18, 2022
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccinationRahul K Suryawanshi, Irene P Chen, Tongcui Ma, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Biorxiv : the Preprint Server for Biology|August 16, 2024
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Immunity|March 21, 2026
Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV reboundTongcui Ma, Ashley F George, Zichong Li, et al.
Journal of Virology|February 4, 2021
Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity <i>Ex Vivo and In Vivo</i>Andrea Gramatica, Roland Schwarzer, William Brantley, et al.
Journal of Medicinal Chemistry|January 6, 2026
Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection ModelsLuca Lizzadro, Jiapeng Li, Taha Y Taha, et al.
Elife|November 19, 2025
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Medrxiv : the Preprint Server for Health Sciences|January 25, 2022
Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without VaccinationRahul K Suryawanshi, Irene P Chen, Tongcui Ma, et al.
JCI Insight|May 17, 2022
Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccinationYusuke Matsui, Lin Li, Mary Prahl, et al.
Science Advances|April 23, 2025
Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M<sup>Pro</sup> inhibitors with potent in vivo efficacyTyler C Detomasi, Gilles Degotte, Sijie Huang, et al.
Cell|April 21, 2026
Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cellsUjjwal Rathore, Eli Dugan, Hunter Thornton, et al.
Nature|May 18, 2022
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccinationRahul K Suryawanshi, Irene P Chen, Tongcui Ma, et al.
Pageof 5